MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

被引:146
作者
Donson, Andrew M.
Addo-Yobo, Steven O.
Handler, Michael H.
Gore, Lia
Foreman, Nicholas K.
机构
[1] Univ Colorado, Hlth Sci Ctr, Aurora, CO 80045 USA
[2] Denver Childrens Hosp, Denver, CO USA
关键词
MGMT promoter methylation; pediatric glioblastoma (GBM); survival; temozolomide;
D O I
10.1002/pbc.20803
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Methylation of the DNA-repair gene O-6-methylguanine-DNA methyltransferase (MGMT) causes gene silencing. This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents. We explored MGMT promoter methylation in pediatric GBM and its relationship to survival and temozolomide sensitivity. Procedure. We performed a retrospective study of MGMT promoter methylation in 10 pediatric GBM. The methylation status of the MGMT was determined using a 2-stage methylation specific PCR analysis on DNA extracted from turnor specimens which had been snap frozen at surgery. The relationships between MGMT promoter methylation and patient outcome and response to temozolomide were evaluated. Results. Four of our 10 pediatric patients with GBM were found to have methylation of the MGMT gene promoter. Methylation of the MGMT promoter was shown to correlate (P=0.0005) with survival. The average survival time for patients with methylated MGMT was 13.7 months as compared to 2.5 months for the 6 patients with unmethylated MGMT promoter. Of the seven patients that received temozolomide, those patients that had the methylated MGMT gene promoter responded better to treatment (P = 0.007). Conclusions. As in adults, pediatric GBM patients with methylated MGMT promoter benefited from temozolomide. However, a stronger correlation with overall survival, regardless of treatment, was observed in this group of patients. These data suggest that MGMT methylation may be a prognostic factor for survival in pediatric GBM, as well as a marker for temozolomide sensitivity. Pediatr Blood Cancer 2007; 48:403-407. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:403 / 407
页数:5
相关论文
共 22 条
[1]   O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines [J].
Bobola, MS ;
Silber, JR ;
Ellenbogen, RG ;
Geyer, JR ;
Blank, A ;
Goff, RD .
CLINICAL CANCER RESEARCH, 2005, 11 (07) :2747-2755
[2]   Protein kinase C ζ isoform is critical for proliferation in human glioblastoma cell lines [J].
Donson, AM ;
Banerjee, A ;
Gamboni-Robertson, F ;
Fleitz, JM ;
Foreman, NK .
JOURNAL OF NEURO-ONCOLOGY, 2000, 47 (02) :109-115
[3]  
Esteller M, 1999, CANCER RES, V59, P793
[4]   Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J].
Esteller, M ;
Garcia-Foncillas, J ;
Andion, E ;
Goodman, SN ;
Hidalgo, OF ;
Vanaclocha, V ;
Baylin, SB ;
Herman, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (19) :1350-1354
[5]   RANDOMIZED PHASE-III TRIAL IN CHILDHOOD HIGH-GRADE ASTROCYTOMA COMPARING VINCRISTINE, LOMUSTINE, AND PREDNISONE WITH THE 8-DRUGS-IN-1-DAY REGIMEN [J].
FINLAY, JL ;
BOYETT, JM ;
YATES, AJ ;
WISOFF, JH ;
MILSTEIN, JM ;
GEYER, JR ;
BERTOLONE, SJ ;
MCGUIRE, P ;
CHERLOW, JM ;
TEFFT, M ;
TURSKI, PA ;
WARA, WM ;
EDWARDS, M ;
SUTTON, LN ;
BERGER, MS ;
EPSTEIN, F ;
AYERS, G ;
ALLEN, JC ;
PACKER, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :112-123
[6]   Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma [J].
Friedman, HS ;
Pluda, J ;
Quinn, JA ;
Ewesuedo, RB ;
Long, L ;
Friedman, AH ;
Cokgor, I ;
Colvin, OM ;
Haglund, MM ;
Ashley, DM ;
Rich, JN ;
Sampson, J ;
Pegg, AE ;
Moschel, RC ;
McLendon, RE ;
Provenzale, JM ;
Stewart, ES ;
Tourt-Uhlig, S ;
Garcia-Turner, AM ;
Herndon, JE ;
Bigner, DD ;
Dolan, ME .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3522-3528
[7]   Clinical relevance of MGMT in the treatment of cancer [J].
Gerson, SL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2388-2399
[8]   Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide [J].
Hegi, ME ;
Diserens, AC ;
Godard, S ;
Dietrich, PY ;
Regli, L ;
Ostermann, S ;
Otten, P ;
Van Melle, G ;
de Tribolet, N ;
Stupp, R .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :1871-1874
[9]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[10]   Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation [J].
Herman, JG ;
Baylin, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2042-2054